Theravance Biopharma Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Theravance Biopharma Inc 公司

Theravance Biopharma, Inc. 是一家生物製藥公司，主要專注於藥物的開發和商業化。其產品 YUPELRI (revefenacin) 吸入溶液適用於慢性阻塞性肺病 (COPD) 患者的維持治療。YUPELRI 是一種處方藥，用於治療 COPD，這是一種長期肺部疾病，包括慢性支氣管炎、肺氣腫或兩者兼有。YUPELRI 是一種抗膽鹼能藥物，可幫助肺部氣道周圍的肌肉保持放鬆，以防止出現喘息、呼吸急促等症狀。安普洛西汀是其後期研究的去甲腎上腺素再攝取抑制劑，正在開發用於治療症狀性神經源性直立性低血壓。

公司簡介

公司代碼TBPH

公司名稱Theravance Biopharma Inc

上市日期May 16, 2014

CEOMr. Rick E. Winningham

員工數量97

證券類型Ordinary Share

年結日May 16

公司地址Ugland House, South Church Street

城市GEORGE TOWN

上市交易所NASDAQ Global Market Consolidated

國家Cayman Islands

郵編KY1-1104

電話16508086000

網址https://www.theravance.com/

公司代碼TBPH

上市日期May 16, 2014

CEOMr. Rick E. Winningham

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Mr. Rick E. Winningham

Chief Executive Officer, Director

1.31M

-2.21%

Dr. Aine Miller

Senior Vice President - Development and Head of Ireland Office

214.99K

+0.34%

Mr. Brett A. Grimaud

Senior Vice President, General Counsel, Secretary

160.16K

-5.73%

Mr. Aziz Sawaf

Chief Financial Officer, Senior Vice President

142.13K

-6.17%

Mr. Eran Broshy

Independent Director

91.20K

+13.22%

Mr. Donal O'Connor

Independent Director

74.20K

+16.76%

Dr. Deepika R. Pakianathan, Ph.D.

Independent Director

58.06K

+22.46%

Ms. Susannah Gray

Independent Chairman of the Board

42.14K

+33.82%

Mr. Jeremy T. Grant

Independent Director

28.54K

+59.52%

Mr. Dean Jonathan (Dean) Mitchell

Independent Director

--

名稱

名稱/職務

職務

持股

持股變動

Mr. Rick E. Winningham

Chief Executive Officer, Director

1.31M

-2.21%

Dr. Aine Miller

Senior Vice President - Development and Head of Ireland Office

214.99K

+0.34%

Mr. Brett A. Grimaud

Senior Vice President, General Counsel, Secretary

160.16K

-5.73%

Mr. Aziz Sawaf

Chief Financial Officer, Senior Vice President

142.13K

-6.17%

Mr. Eran Broshy

Independent Director

91.20K

+13.22%

Mr. Donal O'Connor

Independent Director

74.20K

+16.76%

收入明細

單位: USD更新時間: 7月6日週日

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

暫無數據

地區USD

名稱

營收

佔比

U.S.

64.38M

0.00%

Europe

0.00

0.00%

業務

地區

暫無數據

股東統計

更新時間: 5月17日週六

持股股東

股東類型

持股股東

佔比

Madison Avenue Partners LP

19.02%

Weiss Asset Management

14.91%

Newtyn Management, LLC

9.51%

BlackRock Institutional Trust Company, N.A.

6.07%

Irenic Capital Management LP

5.52%

Other

44.96%

持股股東

佔比

Madison Avenue Partners LP

19.02%

Weiss Asset Management

14.91%

Newtyn Management, LLC

9.51%

BlackRock Institutional Trust Company, N.A.

6.07%

Irenic Capital Management LP

5.52%

Other

44.96%

股東類型

持股股東

佔比

Hedge Fund

59.93%

Investment Advisor

16.82%

Investment Advisor/Hedge Fund

11.60%

Individual Investor

4.71%

Research Firm

2.89%

Bank and Trust

0.23%

Pension Fund

0.19%

Venture Capital

0.04%

Insurance Company

0.03%

Other

3.56%

機構持股

更新時間: 7月1日週二

報告期間

機構數

持股數

持股佔比

持股變動

2025Q2

288

48.24M

96.47%

-10.03M

2025Q1

306

49.02M

97.92%

-10.33M

2024Q4

307

49.22M

100.10%

-11.44M

2024Q3

311

50.46M

103.15%

-9.84M

2024Q2

312

51.86M

106.61%

-21.43M

2024Q1

304

56.26M

115.67%

-11.52M

2023Q4

301

56.96M

111.33%

-13.16M

2023Q3

314

59.36M

109.50%

-14.46M

2023Q2

331

61.03M

103.70%

-24.91M

2023Q1

329

68.16M

106.54%

-18.37M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

Madison Avenue Partners LP

9.51M

19.02%

--

Mar 31, 2025

Weiss Asset Management

7.46M

14.91%

--

Mar 31, 2025

Newtyn Management, LLC

4.76M

9.51%

--

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

3.04M

6.07%

-127.84K

-4.04%

Mar 31, 2025

Irenic Capital Management LP

2.76M

5.52%

--

Mar 31, 2025

The Vanguard Group, Inc.

2.08M

4.16%

+77.48K

+3.87%

Mar 31, 2025

Park West Asset Management LLC

1.80M

3.61%

+11.26K

+0.63%

Mar 31, 2025

Winningham (Rick E)

1.31M

2.61%

-29.60K

-2.21%

Jun 23, 2025

Oasis Management Company Ltd.

1.12M

2.24%

+3.17K

+0.28%

Mar 31, 2025

State Street Global Advisors (US)

1.07M

2.13%

-155.69K

-12.74%

Mar 31, 2025

持股ETF

更新時間: 8月2日週六

機構名稱

佔比

Virtus LifeSci Biotech Products ETF

2%

Invesco NASDAQ Future Gen 200 ETF

0.54%

ALPS Medical Breakthroughs ETF

0.37%

Global X Aging Population ETF

0.35%

iShares U.S. Pharmaceuticals ETF

0.2%

SPDR SSGA US Small Cap Low Volatility Index ETF

0.15%

iShares Micro-Cap ETF

0.09%

Invesco Nasdaq Biotechnology ETF

0.06%

ProShares Ultra Nasdaq Biotechnology

0.06%

Avantis US Small Cap Equity ETF

0.05%

Virtus LifeSci Biotech Products ETF

佔比2%

Invesco NASDAQ Future Gen 200 ETF

佔比0.54%

ALPS Medical Breakthroughs ETF

佔比0.37%

Global X Aging Population ETF

佔比0.35%

iShares U.S. Pharmaceuticals ETF

佔比0.2%

SPDR SSGA US Small Cap Low Volatility Index ETF

佔比0.15%

iShares Micro-Cap ETF

佔比0.09%

Invesco Nasdaq Biotechnology ETF

佔比0.06%

ProShares Ultra Nasdaq Biotechnology

佔比0.06%

Avantis US Small Cap Equity ETF

佔比0.05%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

Theravance Biopharma Inc

11.075USD

Theravance Biopharma Inc

11.075

概覽

公司

財務